Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mupirocin vs Iodophor for Nasal Decolonization in ICU Patients (Swap Out)
NCT03140423Phase 4Completed
- Sponsor
- Harvard Pilgrim Health Care
- Start
- May 2017
- Primary completion
- Nov 2023
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of IVIEW-1502 in Staphylococcus aureus infection, sponsored by Harvard Pilgrim Health Care. Primary endpoint: ICU-attributable Staphylococcus Aureus Clinical Cultures at 18 months. Started May 2017; status: completed.
02
Drugs
IVIEW-1502
03
Conditions
Staphylococcus aureus infection
Beyond the preview
Go deeper on NCT03140423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03140423.